Outcome: After 12 months, drusen size stable on fundus photos, no progression to larger/more numerous drusen
Jensen L, Helleberg H, Roffel A, Jaap van Lier J, Bjornsdottir I, Pedersen PJ, et al
Nuvaxovid targets the following circulating JN.1 lineage strains: LP.8.1, NB.1.8.1, XFG, XFC, LF.7 and XEC
FDA Telehealth Warning Letters In early March 2026, the FDA reportedly issued warning letters to multiple telehealth companies regarding compounded GLP-1 marketing practices, with concerns including misleading marketing claims, implications of equivalence with FDA-approved drugs, and obscuring product sourcing
Many users report experiencing nausea, which is one of the most frequent complaints